Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation
The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic r...
Saved in:
Published in | The Journal of clinical investigation Vol. 59; no. 4; pp. 704 - 715 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.04.1977
|
Subjects | |
Online Access | Get full text |
ISSN | 0021-9738 |
DOI | 10.1172/JCI108689 |
Cover
Loading…
Abstract | The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated. |
---|---|
AbstractList | The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated.The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated. The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in normal subjects and patients by simultaneous administration of radioiodine labeled C5 and C3. In seven normal subjects the fractional catabolic rate of C5 ranged from 1.5 to 2.1% of the plasma pool/h and extravascular/intravascular distribution ratio from 0.22 to 0.78, these values being similar to those obtained for C3, and synthesis rate from 71 to 134 mug/kg per h, In patients with complement activation the increase in fractional catabolic rate of C5 was nearly always less than that of C3. The data also showed that there was increased extravascular distribution of C3 and C5 in most patients and considerable extravascular catabolism of both proteins in some. However, there were differences in metabolic parameters between patients with different types of complement activation. In patients with systemic lupus erythematosus, fractional catabolism and extravascular distribution of C3 and C5 were both increased, and there was marked extravascular catabolism of both proteins. There was increased fractional catabolism and extravascular distribution of C3 in patients with mesangiocapillary nephritis and (or) partial lipodystrophy, and fractional catabolism of C5 was also increased in three of six studies although distribution of C5 was always within the normal range; however, in two patients with nephritic factor in their serum fractional catabolism of C5 was normal despite markedly increased C3 turnover, suggesting that in patients with alternative pathway activation by nephritic factor little or no C5 convertase is generated. |
Author | Liebowitch, J Amos, N Sissons, J G Peters, D K |
Author_xml | – sequence: 1 givenname: J G surname: Sissons fullname: Sissons, J G – sequence: 2 givenname: J surname: Liebowitch fullname: Liebowitch, J – sequence: 3 givenname: N surname: Amos fullname: Amos, N – sequence: 4 givenname: D K surname: Peters fullname: Peters, D K |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/845257$$D View this record in MEDLINE/PubMed |
BookMark | eNptUblOAzEQdRGOJFDQU7hCQiJg79qxt6BAEUdQEA3UltcHMdpdh7UD4if4ZpxD4azsmXeNZnqg0_jGAHCA0SnGLDu7HY0x4kNedEAXoQwPCpbzXdAL4RkhTAglO2CbE5pR1gUfdybK0lcu1NBbGKcGWmfjFCpfz5JvExftRVGZOlUnUDYauhhgayoZnW9g9LD-YxKnrtVfJifQNXCW-Okf4JtbB6w8oVTRvS7N9sCWlVUw--u3Dx6vLh9GN4PJ_fV4dDEZqIznxYAbTaiyBTN5aSyRjBY5oUgqgoasVIZqQ0tkMeZaoazUWtuSMG21lBzjnOd9cL7ync3L2miVpmhlJWatq2X7Lrx04ifSuKl48q8iZ1nGaNIfrfWtf5mbEEXtgjJVJRvj50HwnBOMWJaIh9-DNgmr_Sf4eAWr1ofQGrshYCQW1xSbaybu2S-ucnG5tTShq_5RfAJMvaiP |
CitedBy_id | crossref_primary_10_1371_journal_pone_0195909 crossref_primary_10_1016_0090_1229_89_90139_6 crossref_primary_10_3390_ijms252111679 crossref_primary_10_1074_jbc_M609858200 crossref_primary_10_1016_j_ymthe_2024_02_001 crossref_primary_10_1016_S0307_742X_21_00250_2 crossref_primary_10_1111_j_1445_5994_1989_tb00218_x crossref_primary_10_1002_art_1780291207 crossref_primary_10_1038_nrd4657 crossref_primary_10_1016_S0140_6736_83_90464_6 crossref_primary_10_1007_BF00286138 crossref_primary_10_1111_j_1600_6143_2012_04124_x crossref_primary_10_1182_bloodadvances_2016002832 crossref_primary_10_1016_S0272_6386_12_81018_3 crossref_primary_10_1007_BF00856851 crossref_primary_10_1038_s41598_017_01087_7 crossref_primary_10_1016_S0005_2736_02_00686_7 crossref_primary_10_1371_journal_pone_0187373 crossref_primary_10_1007_BF02431730 crossref_primary_10_1007_BF00292537 crossref_primary_10_1111_imr_13156 crossref_primary_10_2174_0929867326666191016115853 crossref_primary_10_1208_s12248_020_00539_9 crossref_primary_10_1021_acs_bioconjchem_6b00369 crossref_primary_10_1016_0090_1229_90_90144_F crossref_primary_10_1016_S0272_6386_87_80088_4 crossref_primary_10_1038_ki_1984_113 crossref_primary_10_1007_BF00541371 crossref_primary_10_1097_AOG_0000000000002980 crossref_primary_10_1098_rsos_221597 crossref_primary_10_1016_j_dmpk_2018_10_003 crossref_primary_10_1038_ki_1979_51 crossref_primary_10_1016_0090_1229_89_90141_4 crossref_primary_10_1016_S0021_9258_18_55131_0 crossref_primary_10_1038_ki_1988_214 crossref_primary_10_1007_BF00878356 crossref_primary_10_1007_s00281_017_0661_x crossref_primary_10_1111_imr_13165 crossref_primary_10_1016_S0272_6386_12_81068_7 crossref_primary_10_1111_imr_12392 |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.1172/JCI108689 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 715 |
ExternalDocumentID | PMC372275 845257 10_1172_JCI108689 |
Genre | Journal Article Comparative Study |
GroupedDBID | --- -~X .55 .GJ 29K 2WC 3O- 53G 5GY 5RE 8F7 AAWTL AAYXX ABOCM ACGFO ACIHN ACNCT ACPRK ADBBV AEAQA AENEX AFFNX AHMBA AI. ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION CS3 D-I DIK DU5 E3Z EBS EJD EMB F5P FRP GROUPED_DOAJ GX1 HYE H~9 IAO IEA IHR INH IOF IPO J5H KQ8 L7B M1P MVM OK1 OVT P2P P6G RPM TEORI TR2 TVE VH1 VVN W2D WH7 WOQ WOW X7M YOC ZGI ZXP ZY1 .XZ 08G 08P 354 36B 3V. 5RS 7RV 7X7 88A 88E 8AO 8FE 8FH 8FI 8FJ 8R4 8R5 AAKAS AAYOK ABPMR ABUWG ADZCM AFCHL AFKRA ASPBG AVWKF AZFZN BBNVY BCR BCU BEC BENPR BHPHI BKEYQ BLC BPHCQ BVXVI CCPQU CGR CUY CVF EBD ECM EIF EMOBN EX3 FEDTE FYUFA HCIFZ HMCUK HVGLF IHW INR IOV ISR ITC LK8 M0L M5~ M7P N4W NAPCQ NPM OBH OCB ODZKP OFXIZ OGEVE OHH OHT OVD OVIDX PKN PQQKQ PROAC PSQYO Q2X S0X SJFOW SV3 UHU UKHRP XSB YFH YHG YKV ~H1 7X8 5PM |
ID | FETCH-LOGICAL-c2839-8ed45cf97e3bef4a7593450ac4067bce5de5b0f118dc02bdddfb47dfdaa811383 |
ISSN | 0021-9738 |
IngestDate | Thu Aug 21 18:08:46 EDT 2025 Thu Jul 10 19:56:34 EDT 2025 Wed Feb 19 00:21:37 EST 2025 Thu Apr 24 23:11:23 EDT 2025 Tue Jul 01 01:42:47 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 4 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c2839-8ed45cf97e3bef4a7593450ac4067bce5de5b0f118dc02bdddfb47dfdaa811383 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
OpenAccessLink | http://www.jci.org/articles/view/108689/files/pdf |
PMID | 845257 |
PQID | 83841072 |
PQPubID | 23479 |
PageCount | 12 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_372275 proquest_miscellaneous_83841072 pubmed_primary_845257 crossref_primary_10_1172_JCI108689 crossref_citationtrail_10_1172_JCI108689 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 1900 |
PublicationDate | 19770401 |
PublicationDateYYYYMMDD | 1977-04-01 |
PublicationDate_xml | – month: 4 year: 1977 text: 19770401 day: 1 |
PublicationDecade | 1970 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | The Journal of clinical investigation |
PublicationTitleAlternate | J Clin Invest |
PublicationYear | 1977 |
References | 820630 - Immunochemistry. 1976 Apr;13(4):317-24 62010 - J Exp Med. 1976 Oct 1;144(4):1062-75 978134 - J Exp Med. 1976 Oct 1;144(4):1076-93 939051 - Clin Exp Immunol. 1976 Jun;24(3):474-82 1067618 - Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72 13484460 - Phys Med Biol. 1957 Jul;2(1):36-53 4219908 - Clin Exp Immunol. 1974 Nov;18(3):391-405 4817274 - Clin Sci Mol Med. 1974 Feb;46(2):223-9 1185108 - J Exp Med. 1975 Oct 1;142(4):856-63 6074005 - J Clin Invest. 1967 Dec;46(12):2021-34 4143312 - Lancet. 1974 Dec 7;2(7893):1350-2 809512 - J Immunol. 1975 Nov;115(5):1357-61 948757 - Science. 1976 Sep 10;193(4257):1011-3 1165475 - J Exp Med. 1975 Sep 1;142(3):760-72 1245733 - J Immunol. 1976 Jan;116(1):1-7 4468849 - Clin Exp Immunol. 1974 Mar;16(3):445-52 1246331 - N Engl J Med. 1976 Feb 26;294(9):461-5 62817 - J Exp Med. 1976 Nov 2;144(5):1147-63 1097571 - J Exp Med. 1975 Jul 1;142(1):139-50 4160044 - Int Arch Allergy Appl Immunol. 1966;29(2):185-9 4261220 - Immunochemistry. 1972 Jul;9(7):709-23 4627271 - N Engl J Med. 1972 Oct 26;287(17):835-40 4830223 - J Clin Invest. 1974 Jun;53(6):1578-87 5038771 - Clin Exp Immunol. 1972 May;11(1):21-9 950465 - J Immunol. 1976 Aug;117(2):630-4 14316946 - J Exp Med. 1965 Aug 1;122:277-98 1249423 - J Immunol. 1976 Feb;116(2):568-70 4573089 - Ciba Found Symp. 1972;9:113-30 4625395 - Clin Exp Immunol. 1972 Jul;11(3):311-20 1112981 - J Immunol. 1975 Feb;114(2 pt 2):815-22 |
References_xml | – reference: 809512 - J Immunol. 1975 Nov;115(5):1357-61 – reference: 4219908 - Clin Exp Immunol. 1974 Nov;18(3):391-405 – reference: 948757 - Science. 1976 Sep 10;193(4257):1011-3 – reference: 1165475 - J Exp Med. 1975 Sep 1;142(3):760-72 – reference: 820630 - Immunochemistry. 1976 Apr;13(4):317-24 – reference: 978134 - J Exp Med. 1976 Oct 1;144(4):1076-93 – reference: 4160044 - Int Arch Allergy Appl Immunol. 1966;29(2):185-9 – reference: 4573089 - Ciba Found Symp. 1972;9:113-30 – reference: 950465 - J Immunol. 1976 Aug;117(2):630-4 – reference: 14316946 - J Exp Med. 1965 Aug 1;122:277-98 – reference: 1185108 - J Exp Med. 1975 Oct 1;142(4):856-63 – reference: 1097571 - J Exp Med. 1975 Jul 1;142(1):139-50 – reference: 1067618 - Proc Natl Acad Sci U S A. 1976 Sep;73(9):3268-72 – reference: 1112981 - J Immunol. 1975 Feb;114(2 pt 2):815-22 – reference: 1245733 - J Immunol. 1976 Jan;116(1):1-7 – reference: 6074005 - J Clin Invest. 1967 Dec;46(12):2021-34 – reference: 4261220 - Immunochemistry. 1972 Jul;9(7):709-23 – reference: 4627271 - N Engl J Med. 1972 Oct 26;287(17):835-40 – reference: 5038771 - Clin Exp Immunol. 1972 May;11(1):21-9 – reference: 1249423 - J Immunol. 1976 Feb;116(2):568-70 – reference: 4625395 - Clin Exp Immunol. 1972 Jul;11(3):311-20 – reference: 939051 - Clin Exp Immunol. 1976 Jun;24(3):474-82 – reference: 4143312 - Lancet. 1974 Dec 7;2(7893):1350-2 – reference: 1246331 - N Engl J Med. 1976 Feb 26;294(9):461-5 – reference: 4817274 - Clin Sci Mol Med. 1974 Feb;46(2):223-9 – reference: 62010 - J Exp Med. 1976 Oct 1;144(4):1062-75 – reference: 62817 - J Exp Med. 1976 Nov 2;144(5):1147-63 – reference: 13484460 - Phys Med Biol. 1957 Jul;2(1):36-53 – reference: 4468849 - Clin Exp Immunol. 1974 Mar;16(3):445-52 – reference: 4830223 - J Clin Invest. 1974 Jun;53(6):1578-87 |
SSID | ssj0014454 |
Score | 1.3095803 |
Snippet | The metabolism of the fifth component of complement (C5), and its relatonship to metabolism of the third component of complement (C3), has been studied in... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 704 |
SubjectTerms | Adolescent Adult Complement C3 - analysis Complement C3 - metabolism Complement C5 - analysis Complement C5 - metabolism Complement System Proteins - metabolism Female Hepatitis - metabolism Humans Kidney Failure, Chronic - metabolism Lipodystrophy - metabolism Lupus Erythematosus, Systemic - metabolism Male Middle Aged Nephritis - metabolism |
Title | Metabolism of the fifth component of complement, and its relation to metabolism of the third component, in patients with complement activation |
URI | https://www.ncbi.nlm.nih.gov/pubmed/845257 https://www.proquest.com/docview/83841072 https://pubmed.ncbi.nlm.nih.gov/PMC372275 |
Volume | 59 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtswECXcFCh6KbqkqLsSRQ89RK0kkqZ0DIIEqWG7h9qAb4IkkoiKWAoSOYd-RL-5Q5EU5TpAl4sgaBkJes_0kDPzBqEPTJSp5GEYSKLigLI0DXLGwZGTsWA85XnYlYvNF5PzFZ2u2Xo0uh1kLW3b4lP54866kv9BFY4BrrpK9h-Q7Y3CAdgHfGELCMP2rzCeyxYwvNR9LmyoX1WqSyXfXDW1jfJ3SeNmEdBmappYgUmC077nZs9Me1FdC29G3-g1WG9cvrqz2wly3HqIv3sGDvzdvgaz8tIePgfgGxCgMT791Pf7mlUwHMLTTL-qfkn7eGOSAxd-YG9dR2-7bitMZR_ng_wXV1gQBSk3Yi9ucLZy4dVw5aEbabnpWrz_D8C1ouz05ItuIWW6E-2qbC--Zmer2Sxbnq6X99D9GKYXkVvlsdEnSplV7zYvZBWpwPTn3vCuH7M3Ofk9x3bgtCwfo0f26-NjQ50naCTrp-jB3OZTPEM_PYNwozBAjzsG4R56fdgjfYSBPxj4gx1_cNvgzZ6Rjj_eyBGuauzYgzV7BjaxZ88hWp2dLk_OA9uhIyjBLU2DRArKSpVySQqpaM5ZSigL8xLcRF6UkgnJilDBJFaUYVwIIVRBuVAiz5MoIgl5jg5qeJEXCCes4HBjAaYUJROVTvJQh6CpJKRIIzVGH933zkorX6-7qFxm3TSWx1kPzRi97y-9Mpotd130zoGWwYiqw2R5LZvtTZaQhEYhj8fo0EDYG0l0EgAfo8kOtP1prdS-e6auLjrFdsLjmLOXf3zkK_TQ_zJeo4P2eivfgNPbFm87hv4CEeW3ow |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Metabolism+of+the+fifth+component+of+complement%2C+and+its+relation+to+metabolism+of+the+third+component%2C+in+patients+with+complement+activation&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Sissons%2C+J+G&rft.au=Liebowitch%2C+J&rft.au=Amos%2C+N&rft.au=Peters%2C+D+K&rft.date=1977-04-01&rft.issn=0021-9738&rft.volume=59&rft.issue=4&rft.spage=704&rft_id=info:doi/10.1172%2FJCI108689&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon |